New study tests if a lower dose of a stronger blood thinner can prevent heart attacks during stent procedures

NCT ID NCT06228456

Recruiting now Disease control Sponsor: University of Florida Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two blood thinners—low-dose ticagrelor and standard clopidogrel—in 50 stable heart disease patients getting a stent. The goal is to see which drug better prevents blood clots around the time of the procedure. Participants take the assigned drug plus aspirin for about 30 days, and researchers measure platelet activity to determine effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ticagrelor (Brilinta) and clopidogrel (Plavix)
What this could lead to: If successful, this could show that low-dose ticagrelor is a better option than clopidogrel for preventing heart attacks during stent procedures in certain patients.
What could go wrong: This is a small, early-phase study with only 50 participants, so results may not apply to everyone. The benefit may be small or not seen at all, and ticagrelor can cause bleeding or shortness of breath.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE

Contacts and locations

Locations

University of Florida Jacksonville
RECRUITING

Jacksonville, Florida, 32209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.